摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

sery363A | 1204142-02-8

中文名称
——
中文别名
——
英文名称
sery363A
英文别名
3-(1,3-Benzodioxol-5-yl)-5-(3-bromophenyl)-1-(2-fluoroethyl)pyrazole
sery363A化学式
CAS
1204142-02-8
化学式
C18H14BrFN2O2
mdl
——
分子量
389.224
InChiKey
FFRIUVUXVFHPAH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    496.5±45.0 °C(Predicted)
  • 密度:
    1.54±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    24
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    36.3
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    3-(1,3-苯并二恶唑-5-基)-5-(3-溴苯基)-1H-吡唑对甲苯磺酸氟乙酯 在 sodium hydroxide 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 0.25h, 生成 sery363B 、 sery363A
    参考文献:
    名称:
    [EN] NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES
    [FR] NOUVEAU MÉDICAMENT POUR L'INHIBITION DE L'AGRÉGATION DES PROTÉINES IMPLIQUÉES DANS DES MALADIES ASSOCIÉES À L'AGRÉGATION DES PROTÉINES ET/OU DES MALADIES NEURODÉGÉNÉRATIVES
    摘要:
    公开号:
    WO2010000372A3
点击查看最新优质反应信息

文献信息

  • NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES
    申请人:Giese Armin
    公开号:US20110293520A1
    公开(公告)日:2011-12-01
    The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed. Formula (E) wherein X, Y and L are independently nondirectionally selected from —C(R 1 )(R 2 )—, —C(R 3 )═, —N(R 4 )—, —N═, —N + (R 5 )═, —O— and —S—; M and Z are independently nondirectionally selected from formula (I) and formula (II).
    本发明涉及一种由公式(E)表示的化合物。本发明还涉及一种由公式(E)表示的化合物,用于治疗或预防与蛋白质聚集和/或神经退行性疾病相关的疾病。此外,本发明涉及包含本发明化合物的制药和诊断组合物,以及一种试剂盒。此外,本发明还涉及一种成像聚集蛋白沉积物的方法。还公开了一种用于制备可检测标记的本发明化合物的试剂盒。公式(E)中,X、Y和L分别独立地从—C(R1)(R2)—、—C(R3)═、—N(R4)—、—N═、—N+(R5)═、—O—和—S—中非定向选择;M和Z分别独立地从公式(I)和公式(II)中非定向选择。
  • DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES
    申请人:Ludwig-Maximilians-Universität München
    公开号:US20160185730A1
    公开(公告)日:2016-06-30
    The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.
    本发明涉及一种由式(E)所表示的化合物。本发明还涉及一种由式(E)所表示的化合物,用于治疗或预防与蛋白质聚集和/或神经退行性疾病有关的疾病。此外,本发明还涉及包含本发明化合物的制药和诊断组合物,以及一种试剂盒。此外,本发明还涉及一种成像聚集蛋白沉积物的方法。还公开了一种用于制备本发明化合物的可检测标记试剂盒。
  • Drugs for inhibiting aggregation of proteins invoved in diseases linked to protein aggregation and/or neurodegenerative diseases
    申请人:Ludwig-Maximilians-Universität München
    公开号:EP2687513A1
    公开(公告)日:2014-01-22
    The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.
    本发明涉及一种由式(E)代表的化合物。本发明还涉及一种由式(E)代表的化合物,用于治疗或预防与蛋白质聚集相关的疾病和/或神经退行性疾病。此外,本发明还涉及包含本发明化合物的药物和诊断组合物以及试剂盒。此外,本发明还涉及一种对聚集蛋白沉积物成像的方法。本发明还公开了一种用于制备可检测标记的本发明化合物的试剂盒。
  • Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
    申请人:LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN
    公开号:US10435373B2
    公开(公告)日:2019-10-08
    The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.
    本发明涉及一种由式(E)代表的化合物。本发明还涉及一种由式(E)代表的化合物,用于治疗或预防与蛋白质聚集相关的疾病和/或神经退行性疾病。此外,本发明还涉及包含本发明化合物的药物和诊断组合物以及试剂盒。此外,本发明还涉及一种对聚集蛋白沉积物成像的方法。本发明还公开了一种用于制备可检测标记的本发明化合物的试剂盒。
  • NEW DRUGS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES
    申请人:Ludwig-Maximilians-Universität München
    公开号:EP2307381B1
    公开(公告)日:2021-01-13
查看更多